Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Shares Outstanding (2023 - 2025)

CG Oncology (CGON) has disclosed Shares Outstanding for 3 consecutive years, with $80.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 5.95% year-over-year to $80.7 million, compared with a TTM value of $80.7 million through Dec 2025, up 5.95%, and an annual FY2025 reading of $80.7 million, up 5.95% over the prior year.
  • Shares Outstanding was $80.7 million for Q4 2025 at CG Oncology, up from $78.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $80.7 million in Q4 2025 and bottomed at $3.9 million in Q1 2023.
  • Average Shares Outstanding over 3 years is $50.5 million, with a median of $67.1 million recorded in 2024.
  • The sharpest move saw Shares Outstanding soared 1627.96% in 2024, then rose 5.95% in 2025.
  • Year by year, Shares Outstanding stood at $5.2 million in 2023, then soared by 1358.27% to $76.2 million in 2024, then rose by 5.95% to $80.7 million in 2025.
  • Business Quant data shows Shares Outstanding for CGON at $80.7 million in Q4 2025, $78.3 million in Q3 2025, and $76.2 million in Q2 2025.